The recent “ADAURA” clinical study in early-stage EGFRm NSCLC showed a significant increase in disease-free survival (DFS) in patients with stage IB–IIIA who received osimertinib, third generation of EGFR-TKIs, for 3 years as adjuvant treatment after curative resection and/or adjuvant chemotherapy compared with patients who received placebo. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.